Percutaneous cryoablation for inoperable malignant lung tumors: Midterm results

Chou, Hsiao-Ping; Chen, Chun-Ku; Shen, Shu-Huei; Sheu, Ming-Huei; Wu, Mei-Han; Wu, Yu‐Chung; Chang, Cheng-Yen

doi:10.1016/j.cryobiol.2014.12.004

Cited by 13 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant differences were observed in the rates of intrapulmonary hemorrhage between the CA and MWA groups in the present study. The rate of intrapulmonary hemorrhage in the CA group was 24.4%, similar to the 24% reported by Chou et al (45). The rate of intra-pulmonary hemorrhage in the MWA group was 33.9% in the present study, which was higher compared with the 25% incidence rate reported by Yang et al (46).…”

Section: Discussionsupporting

confidence: 84%

Comparing cryoablation and microwave ablation for the treatment of patients with stage�IIIB/IV non‑small cell lung cancer

Das

Huang²,

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

The aim of the present study was to compare the safety and efficacy of cryoablation (CA) and microwave ablation (MWA) as treatments for non-small cell lung cancer (NSCLC). Patients with stage IIIB or IV NSCLC treated with CA (n=45) or MWA (n=56) were enrolled in the present study. The primary endpoint was progression-free survival (PFS); the secondary endpoints included overall survival (OS) time and adverse events (AEs). The median PFS times between the two groups were not significantly different (P=0.36): CA, 10 months [95% confidence interval (CI), 7.5-12.4] vs. MWA, 11 months (95% CI, 9.5-12.4). The OS times between the two groups were also not significantly different (P= 0.07): CA, 27.5 months (95% CI, 22.8-31.2 months) vs. MWA, 18 months (95% CI, 12.5-23.5). For larger tumors (>3 cm), patients treated with MWA had significantly longer median PFS (P=0.04; MWA, 10.5 months vs. CA, 7.0 months) and OS times (P=0.04; MWA, 24.5 months vs. CA, 14.5 months) compared patients treated with CA. However, for smaller tumors (≤3 cm), median PFS (P= 0.79; MWA, 11.0 months vs. CA, 13.0 months) and OS times (P=0.39; MWA, 30.0 months vs. CA, 26.5 months) between the two groups did not differ significantly. The incidence rates of AEs were similar in the two groups (P>0.05). The number of applicators, tumor size and length of the lung traversed by applicators were associated with a higher risk of pneumothorax and intra-pulmonary hemorrhage in the two groups. Treatment with CA resulted in significantly less intraprocedural pain compared with treatment with MWA (P=0.001). Overall, the present study demonstrated that CA and MWA were comparably safe and effective procedures for the treatment of small tumors. However, treatment with MWA was superior compared with CA for the treatment of large tumors.

show abstract

Section: Discussionsupporting

confidence: 84%

Comparing cryoablation and microwave ablation for the treatment of patients with stage�IIIB/IV non‑small cell lung cancer

Das

Huang²,

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The reason is that 64-slice spiral CT can provide good coverage of the ice ball for lesion with ≥ 3 cm and < 3 cm diameters, and improve the ablation effect. Its three-dimensional imaging technology enables physicians to view liver blood vessels and lesions that are more solid, clear, more accurate, and more comprehensive; allowing a reasonable needle puncture and optimizing the freezing effect[11,29,45,46]. Its rapid scan imaging during surgery allows the detection of the formation of ice ball and freezing conditions, provides an accurate lesion and surrounding tissue image, help in the timely adjustment of the ablation procedure, and prevents damage in surrounding tissues, while improving the effectiveness of tumor tissue ablation[9,35,47].…”

Section: Discussionmentioning

confidence: 99%

Observation of the effect of targeted therapy of 64-slice spiral CT combined with cryoablation for liver cancer

Yan¹,

Xu²,

Shen³

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo observe the effect of targeted therapy with 64-slice spiral computed tomography (CT) combined with cryoablation for liver cancer.METHODSA total of 124 patients (142 tumors) were enrolled into this study. According to the use of dual-slice spiral CT or 64-slice spiral CT as a guide technology, patients were divided into two groups: dual-slice group (n = 56, 65 tumors) and 64-slice group (n = 8, 77 tumors). All patients were accepted and received targeted therapy by an argon-helium superconducting surgery system. The guided scan times of the two groups was recorded and compared. In the two groups, the lesion ice coverage in diameter of ≥ 3 cm and < 3 cm were recorded, and freezing effective rate was compared. Hepatic perfusion values [hepatic artery perfusion (HAP), portal vein perfusion (PVP), and the hepatic arterial perfusion index (HAPI)] of tumor tissues, adjacent tissues and normal liver tissues at preoperative and postoperative four weeks in the two groups were compared. Local tumor changes were recorded and efficiency was compared at four weeks post-operation. Adverse events were recorded and compared between the two groups, including fever, pain, frostbite, nausea, vomiting, pleural effusion and abdominal bleeding.RESULTSGuided scan times in the dual-slice group was longer than that in the 64-slice group (t = 11.445, P = 0.000). The freezing effective rate for tumors < 3 cm in diameter in the dual-slice group (81.58%) was lower than that in the 64-slice group (92.86%) (χ2 = 5.707, P = 0.017). The HAP and HAPI of tumor tissues were lower at four weeks post-treatment than at pre-treatment in both groups (all P < 0.05), and those in the 64-slice group were lower than that in the dual-slice group (all P < 0.05). HAP and PVP were lower and HAPI was higher in tumor adjacent tissues at post-treatment than at pre-treatment (all P < 0.05). Furthermore, the treatment effect and therapeutic efficacy in the dual-slice group were lower than the 64-slice group at four weeks post-treatment (all P < 0.05). Moreover, pleural effusion and intraperitoneal hemorrhage occurred in patients in the dual-slice group, while no complications occurred in the 64-slice group (all P < 0.05).CONCLUSION64-slice spiral CT applied with cryoablation in targeted therapy for liver cancer can achieve a safe and effective freezing treatment, so it is worth being used.

show abstract

“…RECIST evaluation after RFA or MWA in comparison to the baseline scan is not effective, due to the limitations of size measurements after ablation. After cryoablation, the downsizing of the ablation zone seems to be faster [80], so that size has a potential value during follow-up, measuring its surface [81], using RECIST [82], or WHO criteria [80]. In cases where the ablation zone remains stable, analysis of contrast enhancement is useful in the determination of the effectiveness of lung ablation [70,75,76,78,83].…”

Section: Follow-up After Thermal Ablation Of Lung Tumorsmentioning

confidence: 99%

“…In cases where the ablation zone remains stable, analysis of contrast enhancement is useful in the determination of the effectiveness of lung ablation [70,75,76,78,83]. When compared to pre-contrast CT, an increase of attenuation of at least 15 HU [82,[84][85][86] or 25 HU [74,79] is described as suggestive of incomplete ablation. Apart from contrast uptake, any increase in size, nodular, irregular, or eccentric solid component appearing within or at the edge of the ablation zone, by comparing to the previous CT image, should be considered as a local recurrence [70,72,74,76,78,85,87,88].…”

Section: Follow-up After Thermal Ablation Of Lung Tumorsmentioning

confidence: 99%

Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice

et al. 2020

View full text Add to dashboard Cite

Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced) ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities, but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies.

show abstract

Percutaneous cryoablation for inoperable malignant lung tumors: Midterm results

Cited by 13 publications

References 34 publications

Comparing cryoablation and microwave ablation for the treatment of patients with stage�IIIB/IV non‑small cell lung cancer

Comparing cryoablation and microwave ablation for the treatment of patients with stage�IIIB/IV non‑small cell lung cancer

Observation of the effect of targeted therapy of 64-slice spiral CT combined with cryoablation for liver cancer

Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice

Contact Info

Product

Resources

About